Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TriSalus Life Sciences, Inc. - Common Stock
(NQ:
TLSI
)
3.630
-0.270 (-6.92%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about TriSalus Life Sciences, Inc. - Common Stock
< Previous
1
2
3
Next >
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
September 22, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
August 31, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Reports Second Quarter 2026 Results
August 06, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 29, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
July 16, 2026
From
TriSalus Life Sciences
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 23, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 17, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 16, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 10, 2026
From
Schall Law
Via
GlobeNewswire
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
June 10, 2026
From
TriSalus Life Sciences
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 09, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 03, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
May 20, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 20, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
May 19, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 19, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
May 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
May 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
May 04, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
April 28, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
April 09, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
April 07, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
March 18, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
March 05, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
February 25, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
February 20, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Proposes Public Offering
February 19, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
February 09, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
January 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
